The screening menu for colorectal cancer just became broader
Updated American Cancer Society guidance released in May 2026 adds two screening options for colorectal cancer, expanding the ways average-risk adults can be checked for disease beginning at age 45. The change reflects growing public attention to colorectal cancer, especially the rise in cases among younger adults, and a push to improve access by giving patients more than one route into screening.
The new guidance does not replace colonoscopy, and it does not change the recommendation that average-risk adults start screening at 45 and continue through 75, or longer if a doctor advises it. Instead, it broadens the set of tools available. For many patients, that could be the practical difference between delaying screening and actually completing it.
That matters because colorectal cancer is one of the clearest examples in medicine where screening can either catch disease early or prevent it altogether by finding precancerous growths before they become malignant. In that context, more acceptable options can translate into better uptake.
What the updated guidelines add
The first newly added option is an at-home stool-based screening test that checks for hidden blood and other molecular markers that may indicate colorectal cancer. The guidelines recommend taking these tests every three years. By combining home collection with molecular analysis, the test is intended to lower logistical barriers for patients who are reluctant to schedule an invasive exam.
The second new option is a blood-based screening test performed at a doctor’s office. The guidance says this test can be chosen by patients who refuse a colonoscopy or a stool-based screening test. That wording is important. The blood test is not presented as the primary preferred route for average-risk adults, but as an alternative for people who would otherwise opt out altogether.
The updated guidance still frames the main choice as one between stool testing and direct visual examination such as colonoscopy. In other words, colonoscopy remains central to screening strategy even as the menu broadens.
Who still needs colonoscopy
The distinction between average-risk patients and higher-risk groups remains critical. For people with a family history of colorectal cancer, genetic or hereditary syndromes, or signs and symptoms such as blood in the stool, colonoscopy is still the only recommended test. That is because higher-risk patients need the most definitive evaluation, and symptoms require diagnostic follow-up rather than simple screening convenience.
This is one reason the new options should not be oversimplified into a message that colonoscopy is no longer necessary. It remains the recommended procedure in several important scenarios, and it is still a core screening pathway for average-risk adults as well.
The practical challenge is that many patients never enter screening at all. Fear, inconvenience, limited access, and reluctance to undergo an invasive procedure can all become obstacles. Offering more routes may help health systems meet people where they are, especially if some patients are willing to start with a home kit or a blood draw when they would not have booked a colonoscopy.
Why the timing matters
The guidance arrives against the backdrop of rising colorectal cancer incidence in people under 50, the same trend that helped drive the American Cancer Society’s 2018 decision to lower the recommended starting age for average-risk screening from 50 to 45. The 2026 update builds on that earlier shift by trying to make screening easier to access and potentially more acceptable.
It also reflects the reality that science and screening technology evolve. Molecular stool testing and blood-based approaches are now mature enough to appear in formal guidance, though the source text notes that many doctors’ offices may not yet offer these newer options widely.
That means the immediate effect may vary depending on local practice. Patients may hear about new tests before their clinics are fully prepared to provide them, and not every provider will have the same workflow or insurance familiarity. Even so, the inclusion of these tests in updated guidance can accelerate adoption over time.
Access, choice, and follow-through
The most important public-health point is that the best screening test is often the one a patient will actually complete, provided it fits the person’s risk category and clinical situation. The updated guidelines lean into that logic without abandoning the more established screening structure.
For clinicians, the change creates more room for shared decision-making. Some patients will still prefer colonoscopy for its directness. Others may be more likely to accept an at-home stool test. A smaller group who refuse both may now have a blood-based option instead of no screening at all.
The revised guidance does not solve every barrier. Follow-up care, availability, and public understanding still matter, and higher-risk patients still need colonoscopy. But by adding newer stool and blood tests to the discussion, the American Cancer Society is acknowledging that expanding screening access is not only about changing the age threshold. It is also about widening the pathway into care.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
